AI Article Synopsis
- COVID-19 can cause systemic inflammation and affect the balance of cytokines that regulate psoriasis.
- Biologics for skin diseases have been studied more during the pandemic compared to other treatments.
- The report describes a patient whose psoriasis worsened after a COVID-19 infection, leading to a change in treatment from secukinumab to adalimumab.
Article Abstract
Coronavirus disease 2019 (COVID-19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune-mediated dermatological diseases have been more extensively studied during the COVID-19 pandemic. Herein, we report a case of flare-up of previously well-controlled psoriasis shortly after infection with COVID-19, with treatment transition from secukinumab to adalimumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568048 | PMC |
| http://dx.doi.org/10.1002/ccr3.8047 | DOI Listing |
Publication Analysis
Top Keywords
transition secukinumab
8
secukinumab adalimumab
8
adalimumab covid-19-induced
4
covid-19-induced psoriasis
4
psoriasis flare-up
4
flare-up treatment
4
treatment case
4
case report
4
report coronavirus
4
coronavirus disease
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!